Cellular carboxypeptidases

被引:137
作者
Skidgel, RA
Erdos, EG
机构
[1] Univ Illinois, Coll Med, Dept Pharmacol MC868, Chicago, IL 60612 USA
[2] Univ Illinois, Coll Med, Dept Anesthesiol, Chicago, IL 60612 USA
关键词
D O I
10.1111/j.1600-065X.1998.tb01577.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This article focuses on four human carboxypeptidases (CPs): two metallo-CPs and two serine CPs. The metallo-CPs are members of the so-called B-type regulatory CP family as they cleave only the C-terminal basic amino acids Arg or Lys. The plasma membrane-bound CPM and the mainly, but nor exclusively, intracellular CPD are surveyed from this group of enzymes. These enzymes can regulate peptide hormone activity at the cell surface and possibly intracellularly after receptor-mediated endocytosis and may also participate in peptide hormone processing. The serine CPs, as their name indicates, contain a serine residue in the active center essential for catalytic activity that reacts with organophosphorus inhibitors. Prolylcarboxypeptidase (PRCP) (angiotensinase C) and deamidase (cathepsin A, lysosomal protective protein) are discussed here. These two enzymes are highly concentrated in lysosomes; however, they may also be active extracellularly after their release from lysosomes in soluble form or in a plasma membrane-bound complex. Whereas deamidase cleaves a variety of peptides with C-terminal or penultimate hydrophobic residues (e.g. substance P angiotensin I, bradykinin, endothelin, fMet-Leu-Phe), PRCP cleaves only peptides with a penultimate Pro residue (e.g. des-Arg(9)-bradykinin, angiotensin II). These enzymes may also be involved in terminating signal transduction by inactivating peptide ligands after receptor endocytosis.
引用
收藏
页码:129 / 141
页数:13
相关论文
共 86 条
[1]  
BHOOLA KD, 1992, PHARMACOL REV, V44, P1
[2]   LYSOSOMAL PROTECTIVE PROTEIN CATHEPSIN-A - ROLE OF THE LINKER DOMAIN IN CATALYTIC ACTIVATION [J].
BONTEN, EJ ;
GALJART, NJ ;
WILLEMSEN, R ;
USMANY, M ;
VLAK, JM ;
DAZZO, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (44) :26441-26445
[3]   THE DEGRADATION PRODUCT OF THE C5A ANAPHYLATOXIN C5A(DESARG) RETAINS BASOPHIL-ACTIVATING PROPERTIES [J].
BURGI, B ;
BRUNNER, T ;
DAHINDEN, CA .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (07) :1583-1589
[4]  
CARRETERO OA, 1989, ENDOCRINE MECHANISMS, P219
[5]  
CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765
[6]  
CRECELIUS DM, 1986, FASEB J, V45, P454
[7]   PROCESSING OF THE NEUROPEPTIDE GROWTH-FACTOR ANTAGONIST [ARG(6), D-TRP(7,9), NMEPHE(8)]-SUBSTANCE-P(6-11) BY A SMALL-CELL LUNG-CANCER CELL-LINE (H69) [J].
CUMMINGS, J ;
MACLELLAN, AJ ;
LANGDON, SP ;
JONES, DA ;
ROZENGURT, E ;
SMYTH, JF .
BIOCHEMICAL PHARMACOLOGY, 1995, 49 (11) :1709-1712
[8]   MOLECULAR DEFECT IN COMBINED BETA-GALACTOSIDASE AND NEURAMINIDASE DEFICIENCY IN MAN [J].
DAZZO, A ;
HOOGEVEEN, A ;
REUSER, AJJ ;
ROBINSON, D ;
GALJAARD, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1982, 79 (15) :4535-4539
[9]   PULSE EXPOSURE TO PROTEIN-SYNTHESIS INHIBITORS ENHANCES VASCULAR-RESPONSES TO DES-ARG9-BRADYKININ - POSSIBLE ROLE OF INTERLEUKIN-1 [J].
DEBLOIS, D ;
BOUTHILLIER, J ;
MARCEAU, F .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 103 (01) :1057-1066
[10]  
DEBLOIS D, 1988, FASEB J, V2, pA1145